For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development | 6,971,005 | 3,987,067* | 9,797,418 | |
| General and administrative | 1,673,890 | 928,945* | 1,953,014 | |
| Total operating expenses | 8,644,895 | 4,916,012 | 11,750,432 | |
| Loss from operations | -8,644,895 | -4,916,012* | -11,750,432 | |
| Change in fair value of financial instruments | - | 1,398* | - | |
| Other income | 400,523 | -64,155* | 170,306 | |
| Total other income, net | - | -62,757* | 170,306 | |
| Net loss | -8,244,372 | -4,978,769 | -11,580,126 | |
| Basic EPS | -1.26 | 0.11 | -0.24 | |
| Diluted EPS | -1.26 | 0.11 | -0.24 | |
| Basic Average Shares | 6,527,779 | -45,320,111 | 48,833,799 | |
| Diluted Average Shares | 6,527,779 | -45,320,111 | 48,833,799 | |
ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences Inc. (PMN)